Chapter 52. The Role of Hematopoietic Growth Factors in Managing Patients with Hematologic Malignancies

  1. Mark A. Crowther MD, MSc, FRCPC Professor Division Director6,7,
  2. Jeff Ginsberg MD, FRCPC Professor8,
  3. Holger J. Schünemann MD, PhD, MSc, FACP, FCCP Professor9,10,
  4. Ralph M. Meyer MD, FRCPC Director Professor11,12 and
  5. Richard Lottenberg MD, FACP Professor13
  1. Heloisa P. Soares MD1,
  2. Ambuj Kumar MD, MPH2,
  3. Charles Bennett MD, PhD3,4 and
  4. Benjamin Djulbegovic MD, PhD5

Published Online: 4 FEB 2009

DOI: 10.1002/9781444300857.ch52

Evidence-Based Hematology

Evidence-Based Hematology

How to Cite

Soares, H. P., Kumar, A., Bennett, C. and Djulbegovic, B. (2009) The Role of Hematopoietic Growth Factors in Managing Patients with Hematologic Malignancies, in Evidence-Based Hematology (eds M. A. Crowther, J. Ginsberg, H. J. Schünemann, R. M. Meyer and R. Lottenberg), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444300857.ch52

Editor Information

  1. 6

    Division of Hematology, McMaster University, Hamilton, Ontario, Canada

  2. 7

    St. Joseph's Hospital, Hamilton, Ontario, Canada

  3. 8

    Department of Medicine, McMaster University, Hamilton, Canada

  4. 9

    CLARITY Research Group, Department of Epidemiology, Italian National Cancer Institute Regina Elena, Rome, Italy

  5. 10

    McMaster University, Hamilton, Canada

  6. 11

    National Cancer Institute of Canada, Clinical Trials Group, Edith Eisenhauer Chair in Clinical Cancer Research, Queen's University, Kingston, Ontario, Canada

  7. 12

    Departments of Oncology and Medicine, Queen's University, Kingston, Ontario, Canada

  8. 13

    Division of Hematology/Oncology, Department of Medicine, University of Florida College of Medicine, Gainesville, Florida, USA

Author Information

  1. 1

    Department of Internal Medicine, Mount Sinai Medical Center, Miami Beach, Florida, USA

  2. 2

    Department of Health Outcomes and Behavior and Oncologic Sciences, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida, USA

  3. 3

    Division of Hematology/Oncology, Department of Medicine, Feinberg School of Medicine, Mid-West Center for Health Services Policy Research, Chicago VA, USA

  4. 4

    Lakeside Division, Northwestern University Medical School, Chicago, Illinois, USA

  5. 5

    Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida, USA

Publication History

  1. Published Online: 4 FEB 2009
  2. Published Print: 27 JUN 2008

ISBN Information

Print ISBN: 9781405157476

Online ISBN: 9781444300857

SEARCH

Keywords:

  • patients with hematologic malignancies;
  • primary prophylaxis and use of growth factors before neutropenia;
  • established fever and neutropenia;
  • Consensus guidelines of National Comprehensive Cancer Network;
  • American Society for Clinical Oncology;
  • secondary prophylaxis - use of G-CSF in subsequent chemotherapy cycles;
  • primary prophylaxis associated with significant reductions in relative risk of febrile neutropenia

Summary

This chapter contains sections titled:

  • Introduction

  • Questions

  • Literature-search strategy and inclusions

  • Do patients with hematologic malignancies benefit from the addition of EPO in the treatment of chemotherapy-induced anemia?

  • What are the benefits and harms associated with the use of CSFs as primary prophylaxis of chemotherapy-induced febrile neutropenia?

  • References